OmniAb (OABI) Q3 2024 earnings summary

Executive summary

• Achieved robust growth in partner and program base, reaching 86 active partners and 352 active programs as of September 30, 2024, including 33 clinical-stage and approved products.

• Continued innovation with launches of OmniDab and OmniHub, and expansion of proprietary technologies to meet evolving partner needs.

• Signed three new platform license agreements in Q3 2024, expanding relationships with leading institutions and companies.

• Clinical pipeline advanced with multiple new clinical trial entries, including programs from Genmab, Merck KGaA, Immunovant, Teva, and BioCity.

• Over $550 million in potential milestones from preclinical and later-stage programs.

Financial highlights

• Q3 2024 total revenue was $4.2 million, down from $5.5 million in Q3 2023, mainly due to lower milestone and service revenue.

• Net loss for Q3 2024 was $16.4 million ($0.16/share), compared to $15.7 million ($0.16/share) in Q3 2023.

• Operating expenses for Q3 2024 were $23.9 million, down 7% year-over-year; R&D expense was $13.3 million and G&A expense was $7.1 million.

• Cash, cash equivalents, and short-term investments totaled $59.4 million as of September 30, 2024.

• Nine-month 2024 revenue was $15.6 million, down from $29.3 million in 2023, reflecting a prior-year $10 million milestone.

Outlook and guidance

• Expect to end 2024 with $50–$60 million in cash, including recent ATM proceeds.

• Project lower cash use in 2025 compared to 2024, excluding ATM proceeds.

• Anticipate certain development milestones in Q4 2024, with some cash collections possibly delayed to Q1 2025.

• Continue to expect 1–3 additional clinical entries for OmniAb-derived antibodies by year-end.

• Management expects current liquidity to support operations for at least the next 12 months.